Qiagen N.V. Expands into Bloodstream Infection Syndromic Testing with New Rapid QIAstat-Dx Panel

Published: 2026-04-14 16:50:34 ET QGEN

Published on 04/14/2026 at 04:50 pm EDT

QIAGEN N.V. had announced its expansion into syndromic testing for bloodstream infections with the launch of the CE-IVDR-certified QIAstat-Dx BCID GPF Plus AMR Panel. The launch of this new QIAstat-Dx panel coincides with the ESCMID Global 2026 Congress in Munich (April 17?21), where QIAGEN will highlight its broad infectious disease portfolio, including QIAstat-Dx, the QuantiFERON-TB Gold Plus test for tuberculosis detection, alongside additional technologies supporting laboratory workflows, clinical decision-making and the development of Laboratory Developed Tests (LDTs). The QIAstat-Dx BCID GPF Plus AMR Panel enables laboratories to identify 20 gram-positive bacterial and fungal pathogen targets (GPF) and 10 antimicrobial resistance (AMR) markers from positive blood cultures and pure colonies.

This launch expands the QIAstat-Dx portfolio beyond respiratory, gastrointestinal and meningitis /encephalitis testing into bloodstream infection applications. In bloodstream infections, timely identification of pathogens and resistance markers is critical, as treatment decisions often need to be made quickly. By delivering results in about one hour, the QIAstat-Dx BCID GPF Plus AMR Panel is designed to support laboratory workflows while providing clinically relevant information for patient management, antimicrobial stewardship and infection control efforts.

QIAstat-Dx integrates sample preparation, molecular testing and data analysis into a single workflow. The systems are available in more than 100 countries, with more than 5,200 instruments placed worldwide as of the end of 2025.